Identifying Outcomes of Patients With Advanced Pancreatic Adenocarcinoma and RECIST Stable Disease Using Radiomics Analysis

Qiuxia Yang, MD¹; Yize Mao, MD²; Hui Xie, MD¹; Tao Qin, MD³; Zhijun Mai, MD¹; Qian Cai, MD⁴; Hailin Wen, MD⁵; Yong Li, MD⁶; Rong Zhang, MD¹; and Lizhi Liu, MD¹

PURPOSE Few studies have explored the biomarkers for predicting the heterogeneous outcomes of patients with advanced pancreatic adenocarcinoma showing stable disease (SD) on the initial postchemotherapy computed tomography. We aimed to devise a radiomics signature (RS) to predict these outcomes for further risk stratification.

MATERIALS AND METHODS Patients with advanced pancreatic adenocarcinoma and SD after chemotherapy were included. Pancreatic lesions on initial postchemotherapy computed tomography images were evaluated by radiomics analysis for predicting early death (≤ 1 year). RS was then internally and externally tested. The progression-free survival and objective response rate were compared between the low-risk and high-risk group of patients classified following RS.

RESULTS Approximately 62.7% of patients receiving chemotherapy showed SD at first response evaluation in the primary cohort, which were 59.6% and 57.9% in internal and external testing cohorts, respectively. The RS predicted 1-year overall survival well, with areas under the receiver operating characteristic curve of 0.91 in the training cohort, 0.90 in the validation cohort, 0.84 in the internal testing cohort, and 0.87 in the external testing cohort. The high-risk group had a shorter median progression-free survival (7.3 months v 9.0 months, \( P = .016 \), in the training cohort; 5.9 months v 9.2 months, \( P = .026 \), in the internal testing cohort) and a lower objective response rate (2.2% v 24.0% in the training cohort) than the low-risk group. In addition, RS was not related to the clinical characteristics and chemotherapy regimens.

CONCLUSION RS independently predicts the outcomes of patients with SD after chemotherapy well and can help to improve treatment decisions by identifying patients for whom current treatment may not be suitable.

JCO Precis Oncol 6:e2100362. © 2022 by American Society of Clinical Oncology

INTRODUCTION Advanced pancreatic adenocarcinoma (PAC) is associated with poor outcomes,¹ with a median overall survival (OS) of 11.1 months.² Recent developments in precision oncology have improved PAC treatment; for example, a PARP inhibitor can be used for PACs with a BRCA1 mutation.³ However, 4%-7% of patients with PAC have BRCA1 mutation.³ Thus, traditional chemotherapy using FOLFIRINOX or adopting a gemcitabine-based regimen remains the main treatment for PAC.³ The majority of patients (range 53%-80%) show stable disease (SD) on the initial postchemotherapy computed tomography (CT), according to the RECIST 1.1.⁴⁻⁵ Thus, improving outcomes in patients showing SD using precision oncology methods is important.

In clinical practice, we observed that the outcomes of patients with PAC with SD were heterogeneous. Some patients survive longer than 12 months, whereas the disease progresses rapidly in some (survival period, not more than 6 months).⁹,¹⁰ Disappointingly, under current circumstances, all patients diagnosed with SD still continue the primary chemotherapy regimen until the tumor progresses, regardless of these widely varying outcomes. These findings indicate that the RECIST is not the optimal biomarker for assessing whether the current chemotherapy regimen should be continued or discontinued in patients with SD. Therefore, it is urgent to explore a new model for further risk stratification to distinguish a subgroup of patients with SD who could potentially benefit from treatment.

To date, there has been no comprehensive study of biomarkers that can predict the outcomes in patients with PAC with SD early after first-line chemotherapy. Various biohumoral markers (eg, carbohydrate antigen [CA] 19-9,¹¹,¹² circulating ribonucleic acids,¹³,¹⁴ circulating tumor cell DNA,¹⁵,¹⁶ or gene signatures)¹⁷⁻¹⁹ have been associated with the outcomes of PAC. However, they are insufficient to stratify patients with...
SD accurately (eg, CA 19-9) or they are impractical in actual clinical settings (eg, circulating tumor DNA and gene signatures), because of their exorbitant cost, long turnaround time, reliance on bioinformatics expertise, or requirement of more than the limited specimen obtained by biopsy.

Radiomics analysis on the basis of tumor heterogeneity has great potential in efficacy evaluation and prognosis prediction in patients with PAC and many other malignancies. Radiomics captures heterogeneity across the entire tumor volume. However, previously published prognostic models on PAC have focused on the pretreatment CT texture features, as known treatment options for patients with advanced PAC are scarce, and the current first-line treatment cannot be changed, even if the baseline imaging findings suggest a worse outcome. By contrast, if survival can be predicted by the early CT features after standard chemotherapy, it will be helpful to determine whether high-risk patients need a more aggressive regimen or could participate in exploratory research. Therefore, the prognostic model using the initial CT radiomics features after chemotherapy may perform better. Furthermore, the basic radiomics workflow and radiomics features are well defined. CT data acquisition is a simpler approach for the management of PAC because of its lower cost and widespread availability. Moreover, it does not incur additional costs for patients. Thus, CT-based radiomics analysis can be readily translated into the clinic.

Therefore, this retrospective study aimed to use radiomics analysis to predict the outcomes in patients with advanced PAC and SD on initial CT images after first-line chemotherapy for further risk stratification to assist clinicians with decision making.

MATERIALS AND METHODS

Patients

Patients with pathologically proven advanced PAC who received chemotherapy at our center during August 2010 to March 2020 and showed SD at first response evaluation were reviewed. The Data Supplement presents the detailed inclusion and exclusion criteria, and the CONSORT diagram of patient selection is shown in Appendix Figure A1. Eligible patients were randomly divided into a training and a validation cohort by a computer algorithm in a ratio of 7:3. According to the above criteria, eligible patients in our center during April 2020 to April 2021 and those patients in center 2 during January 2013 to December 2020 were enrolled as independent internal and external testing cohorts, respectively (Fig 1A).

Clinical data (eg, sex, age, tumor location, size, T stage, American Joint Committee on Cancer stage, and multiple organ metastasis [yes/no]) at baseline, CA 19-9 levels at baseline and after chemotherapy (the same period as the first follow-up CT), and chemotherapy regimens were obtained from medical records. The change ratio of CA 19-9 was calculated using the following formula: (CA 19-9 level at baseline – CA199 level after chemotherapy)/CA 19-9 level at baseline, and recorded as the CA19-9 ratio.

Treatment and Follow-up

The treatment regimens and follow-ups are shown in the Data Supplement. Patients were followed up for survival duration until November 2021. The OS was defined as the time from the start of chemotherapy to the date of death because of any cause or date of the last follow-up.

Assessment of Chemotherapy Efficacy

For all patients, the efficacy assessment was performed on all continuous follow-up CT examinations after chemotherapy, according to RECIST 1.1. Two experienced radiologists (one with >10 years of subspecialty experience in pancreatic cancer and one with 5 years of experience) independently reviewed the CT images of each patient. The readers were
Radiomics Signature: Construction and Validation

Patients were grouped according to outcomes into better (OS ≥ 1 year) and worse outcome groups (OS < 1 year). In the training cohort, we developed a prediction model using the radiomics features of the first follow-up CT after chemotherapy to distinguish between the two groups. The discrimination performance of established models was quantified by receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) value. The corresponding cutoff value of the rad-score was calculated.

Clinical Use of Decision Curve Analysis

To evaluate the added value of the RS to individual clinical features in predicting a < 1-year OS for patients with advanced PAC with SD, we developed four decision curves, on the basis of the radiomics model: T stage, CA 19-9 level at baseline, CA 19-9 ratio, and tumor size). The clinical utility could be demonstrated by calculating the net benefits for a range of threshold probabilities.

Comparison of the Serial Tumor Response Between the High-Risk and Low-Risk Groups

On the basis of the rad-score cutoff value, we classified patients into two groups: low-risk and high-risk groups. To
compare the difference in tumor progression, the progression-
free survival (PFS) in the two groups was statistically com-
pared. The PFS end point was defined as the time from the
start of chemotherapy to the date of tumor progression or
death because of any cause. The chemotherapy regimens
were also compared between the two groups.
To compare the tumor response in the high-risk and low-
risk groups, the complete response (CR) or partial response
(PR) from patients in the follow-up duration and intervals
was recorded. The ORRs (proportion of patients with a PR
or CR as the best response) in the two groups were cal-
culated and compared. The maximal percentage reduction
in the size of pancreatic lesions was calculated.

**Statistical Analyses**

Clinical characteristics between the four cohorts and be-
tween the high-risk and low-risk groups were compared
using the chi-squared test. Univariate logistic analysis was
used to assess the possible association of each predictor of
the outcome variable. The difference in the objective re-
response rate (ORR) between the high-risk and low-risk
groups was analyzed using the chi-squared test. The ROC
curve and AUC were applied to evaluate the predictive
power of each model. The Data Supplement describes the
software for statistical analysis.

**RESULTS**

**Patient Characteristics**

In the primary cohort in our center, 62.7% (324 of 517
patients) of patients showed SD at the first response
evaluation (Appendix Fig A1A). As per the inclusion criteria,
101 patients (median, 57 years; range, 34-78 years; 58
women) with SD were included and divided into a training
and a validation cohort (Fig 1A). In addition, two testing
cohorts were enrolled as follows: 33 patients from our
center were used as the independent internal testing cohort
and 25 patients from center 2 as the external testing cohort
(Fig 1A). In total, 59.6% and 57.9% of patients in the
internal (Appendix Fig A1B) and external testing cohorts
(Appendix Fig A1C) showed SD at the first response
evaluation, respectively. The baseline characteristics of all
patients are summarized in Table 1. There were no dif-
fferences in clinical characteristics between the training
and validation cohorts.

The median follow-up durations of OS were 11.6 (95% CI,
10.1 to 14.3) months, 13.1 (95% CI, 9.5 to 15.5) months,
10.0 (95% CI, 6.5 to 12.9) months, and 9.4 (95% CI, 6.4 to
11.4) months in the training, validation, internal testing,
and external testing cohorts, respectively. After univariate
analysis, the clinical features showed no correlation with OS
in the training cohort (Data Supplement).

**RS Construction**

The study workflow is shown in Figure 1B. Of the 1,540
extracted radiomics features, after five selection processes
(Data Supplement and Appendix Fig A2), six texture
features were selected to build the RS. The rad-score was
calculated for each patient using the formula described in
the Data Supplement.

Among the six features, three were features of the gray-level
cocurrence matrix and the other three were features of
the gray-level run-length matrix. The features were dis-
tributed in each phase, and three (50%) of them were
found in the venous phase. The contributing weight of each
feature in the formula is shown in Appendix Fig A3. The
features of the RS are described in the Data Supplement.

**Validation of RS**

The ROC curves of the clinical features and radiomics model
are presented in Figure 2. The RS yielded higher AUCs of
0.91 (95% CI, 0.83 to 0.97) and 0.90 (95% CI, 0.79 to 0.99)
in the training and validation cohorts, respectively, com-
pared with those of the T-stage model (AUCs = 0.53 and
0.58 in the training and validation cohorts, respectively), the
CA 19-9 model (AUCs = 0.51 and 0.52, respectively), the
CA19-9 ratio model (AUCs = 0.65 and 0.63, respectively), or
the tumor size model (AUCs = 0.55 and 0.42, respectively),
showing favorable predictive efficacy. Two testing cohorts
obtained similar results; the RS yielded higher AUCs of 0.84
(95% CI, 0.68 to 0.99) and 0.87 (95% CI, 0.71 to 1.0) in the
internal and external testing cohorts, respectively. The RS
achieved a sensitivity and specificity of 82% and 86%,
respectively, for predicting a < 1-year OS, at an optimal rad-
score cutoff value of 0.46.

**Clinical Use of Decision Curve Analysis**

The decision curve analysis (DCA) for the radiomics model
and that for the models with a single clinical predictor (T
stage, CA 19-9 level at baseline, CA19-9 ratio, and tumor
size) are presented in Appendix Fig A4. The final DCA
showed that the radiomics model provided a better net
benefit for predicting a < 1-year OS than the other four
models for threshold probabilities of more than 10%, in-
dicating that, within this range, the rad-score outperformed
the clinical features with more accuracy in a < 1-year OS
prediction.

**Comparison of PFS**

According to the rad-score cutoff value (0.46), we classified
the patients into a low-risk (rad-score > 0.46) and a high-
risk group (rad-score ≤ 0.46). The median PFSs were 9.0
(95% CI, 5.5 to 18.5) months versus 7.3 (95% CI, 6.1 to
8.8) months (P = .016; training cohort, Fig 3A), 13.5 (5.9 to
16.7) months versus 6.7 (4.8 to 11.3) months (P = .42;
validation cohort, Fig 3B), 9.2 (4.7 to 18.4) months versus
5.9 (4.2 to 7.3) months (P = .026; internal testing cohort,
Fig 3C), and 7.3 (5.1 to 13.3) months versus 6.0 (4.7 to 6.7)
months (P = .15; external testing cohort, Fig 3D) in the low-
risk and high-risk groups, respectively.

There was no significant difference in the first-line che-
motherapy regimens between the high-risk and low-risk
groups in the training (P = .81), validation (P = .65), internal
TABLE 1. Clinical Characteristics of the Patients

| Characteristic               | Training Cohort (n = 70) | Validation Cohort (n = 31) | Internal Testing Cohort (n = 33) | External Testing Cohort (n = 25) | P* |
|-----------------------------|--------------------------|---------------------------|---------------------------------|---------------------------------|----|
| Sex                         |                          |                           |                                 |                                 |    |
| Male                        | 28                       | 15                        | 17                              | 16                              | .57 |
| Female                      | 42                       | 16                        | 16                              | 9                               | .21 |
| Age (years)                 |                          |                           |                                 |                                 | .14 |
| Median (range)              | 57 (34-78)               | 57 (41-73)                | 59 (30-78)                      | 55 (38-66)                      |    |
| < 65                        | 50                       | 27                        | 22                              | 22                              | .14 |
| ≥ 65                        | 20                       | 4                         | 11                              | 3                               | .09 |
| Tumor location              |                          |                           |                                 |                                 |    |
| Head or neck                | 32                       | 14                        | 13                              | 15                              | .99 |
| Body or tail                | 38                       | 17                        | 20                              | 10                              | .46 |
| Tumor size                  |                          |                           |                                 |                                 |    |
| Median (range)              | 48 (26-102)              | 45 (25-128)               | 44 (21-78)                      | 38 (21-79)                      |    |
| < 40 mm                     | 19                       | 7                         | 11                              | 13                              | .81 |
| ≥ 40 mm                     | 51                       | 24                        | 22                              | 12                              | .08 |
| T stage                     |                          |                           |                                 |                                 |    |
| T2                          | 3                        | 3                         | 2                               | 4                               | .56 |
| T3                          | 13                       | 6                         | 14                              | 2                               | .02 |
| T4                          | 54                       | 22                        | 17                              | 19                              |    |
| AJCC stage                  |                          |                           |                                 |                                 |    |
| III                         | 24                       | 14                        | 6                               | 5                               | .41 |
| IV                          | 46                       | 17                        | 27                              | 20                              | .06 |
| Multiple organ metastasis   |                          |                           |                                 |                                 |    |
| Yes                         | 17                       | 3                         | 6                               | 11                              | .15 |
| No                          | 53                       | 28                        | 27                              | 14                              | .02 |
| CA 19-9 at baseline (U/mL)b |                          |                           |                                 |                                 |    |
| < 450                       | 31                       | 16                        | 14                              | 10                              | .64 |
| ≥ 450                       | 39                       | 15                        | 17                              | 12                              | .92 |
| CA 19-9 ratio<sup>c</sup>   |                          |                           |                                 |                                 |    |
| Median (IQR)                | -0.03 (-0.45-0.22)       | -0.01 (-0.37-0.47)        | -0.05 (-0.7-0.47)               | -0.33 (-0.64-0.04)              | .48 |
| ≤ 0.02                      | 43                       | 16                        | 18                              | 16                              | .47 |
| > 0.02                      | 27                       | 15                        | 13                              | 6                               |    |
| Chemotherapy regimen        |                          |                           |                                 |                                 | .11 |
| Gemcitabine-based           | 46                       | 14                        | 21                              | 9                               |    |
| FOLFIRINOX or modified FOLFIRINOX | 10                   | 5                         | 4                               | 13                              |    |
| SOXIRI                      | 14                       | 12                        | 8                               | 3                               |    |
| OS, median (95% CI), months | 11.6 (10.1 to 14.3)      | 13.1 (9.5 to 15.5)        | 10.0 (6.5 to 12.9)              | 9.4 (6.4 to 11.4)               | .48 |

Abbreviations: AJCC, American Joint Committee on Cancer; CA 19-9, cancer antigen 19-9; FOLFIRINOX, fluorouracil, leucovorin, irinotecan, and oxaliplatin; IQR, interquartile range; OS, overall survival; SOXIRI, S-1/oxaliplatin/irinotecan.

*Chi-square test for the four groups.

<sup>b</sup>The CA 19-9 results at baseline of two patients in the internal testing cohort and three patients in the external testing cohort were missing.

<sup>c</sup>CA19-9 ratio = (CA19-9 level after chemotherapy – CA 19-9 level at baseline)/CA 19-9 level at baseline. The cutoff value was the mean value of the CA 19-9 ratio of the training cohort.

<sup>d</sup>T-test for the two testing cohorts.
testing \((P = .14)\), and external testing cohorts \((P = .08; \text{Table 2 and Data Supplement})\). Other clinical features showed no difference between the two groups (Data Supplement).

**Serial Tumor Response After Chemotherapy in the Primary Cohort**

As shown in Figures 4 and 5 and Appendix Figure A5, six and one patient(s) in the low-risk and high-risk groups in the training cohort achieved the best response of PR after chemotherapy, respectively; furthermore, four and one patient(s) in the low-risk and high-risk groups in the testing cohort achieved the same, respectively. No patients achieved a PR at \(> 9\) months or a CR in both groups. The ORRs were \(24.0\%\) (6 of 25 patients) and \(2.2\%\) (1 of 45 patients) in the low-risk and high-risk groups in the training cohort \((P = .007)\) and \(26.7\%\) (4 of 15 patients) and \(6.3\%\) (1 of 16 patients) in the corresponding groups in the validation cohort, respectively \((P = .172; \text{Table 2})\). For all 12 patients with PR, the median maximal percentage reduction in the size of primary pancreatic lesions was \(39.2\%\) (range, \(19.5\%-47.9\%\)).

**DISCUSSION**

To the best of our knowledge, no previous study has used radiomics analysis to predict the outcomes in patients with advanced PAC with SD on the basis of initial CT after first-line chemotherapy for further risk stratification. In this study, the majority (62.7%) of patients with advanced PAC...
showed SD on the initial CT after chemotherapy, which agreed with previously reported results.5,6,8 The high-risk group had a shorter PFS in the training and internal testing cohorts and a lower ORR than the low-risk group in the training cohort; consequently, the high-risk group had shorter OS than the low-risk group, with marked differences

**FIG 3.** PFS of patients stratified by risk classification according to the rad-score (cutoff value, 0.46) in the four cohorts: (A) training, (B) validation, (C) internal testing, and (D) external testing cohorts. PFS, progression-free survival.

**TABLE 2.** Comparison of the Tumor Response Between the High-Risk and Low-Risk Groups in the Primary Cohort

| Comparison Variables                  | Training Cohort                | Validation Cohort               |
|--------------------------------------|--------------------------------|---------------------------------|
|                                      | Low-Risk Group (n = 25)        | High-Risk Group (n = 45)        | Low-Risk Group (n = 15)        | High-Risk Group (n = 16) |
| Chemotherapy regimens, No. (%)       |                                |                                 |                                |                          |
| Gemcitabine-based                    | 17 (68.0)                      | 29 (64.4)                      | 6 (40.0)                       | 8 (50.0)                 |
| FOLFIRINOX or modified FOLFIRINOX    | 4 (16.0)                       | 6 (13.3)                       | 1 (6.7)                        | 2 (12.5)                 |
| SOXIRI                               | 4 (16.0)                       | 10 (22.2)                      | 8 (53.3)                       | 6 (37.5)                 |
| ORR                                  | 6 of 25                        | 1 of 45                        | 4 of 15                        | 1 of 16                  |
| Proportion of patients who remained with SD at 8 months | 3 of 25                        | 8 of 45                        | 5 of 15                        | 2 of 16                  |
| Proportion of patients with PD during the 8-month follow-up | 10 of 25                       | 14 of 45                       | 3 of 15                        | 10 of 16                 |

Bold indicates $P < .05$.

Abbreviations: FOLFIRINOX, fluorouracil, leucovorin, irinotecan, and oxaliplatin; ORR, objective response rate, proportion of patients with a partial response or complete response as the best response; PD, progressive disease; SD, stable disease; SOXIRI, S-1/oxaliplatin/irinotecan.
in the outcomes among patients with SD. The present RS demonstrated favorable predictive efficacy and can help oncologists to devise individualized therapy in patients with SD. The lack of specific biomarkers for predicting the outcomes of patients with advanced PAC who underwent chemotherapy remains one of the biggest barriers to improve the outcomes of advanced PAC. In these patients with SD, we found that the tumor size, age, sex, and CA19-9 levels at baseline were not related to the OS. In contrast to the above parameters, the RS was strongly and significantly prognostic: the high-risk group had shorter survival outcomes than the low-risk group. Recent studies have shown that higher tumor heterogeneity was positively correlated with a poor response to chemotherapy or chemoradiotherapy in patients with PAC.\textsuperscript{21,22} In this study, the parameters in the RS were part of the gray-level co-occurrence matrix and gray-level run-length matrix; these are also known as second-order texture features. The superiority of these features can be explained by the fact that they capture the spatial arrangement and distribution of intensities within the target lesions. Moreover, half of the six parameters were present in the venous phase, and the first two parameters with the largest weight coefficient were also in the venous phase. This may be associated with the abundant interstitial fibrosis and delayed enhancement of pancreatic cancer. The heterogeneity of density in the venous phase leads to differences in tumor heterogeneity. This group of features was also the most frequently observed significant radiomics features in PAC in previous studies.\textsuperscript{23,24,32} The above data could partially explain why the RS could predict the outcome after chemotherapy well. Taken together, the RS could help oncologists to improve treatment decisions by identifying patients who will not benefit from current chemotherapy, but who may benefit from a more aggressive treatment approach or enrollment in a clinical trial.

Furthermore, one of the major merits of the widely used efficacy evaluation method, the RECIST, was independence of the types of chemotherapy regimens. Our analysis showed that the RS was not related to the clinical characteristics and chemotherapy regimens, suggesting that the RS could also be clinically useful for further efficacy evaluation and prediction in patients with advanced PAC and SD after chemotherapy.

![Diagram](image-url)
Moreover, after continuous efficacy evaluation, we found that the ORR in the high-risk group was markedly lower than that in the low-risk group (2.2% vs 24.0% in the training cohort). These findings indicated that the patients in the high-risk group have a significantly lower probability of achieving PR than those in the low-risk group. More

FIG 5. The tumor response after chemotherapy in patients in the (A) low-risk and (B) high-risk groups. The detailed legends of each image are described in the Data Supplement.
specifically, as only a few patients (1 of 45 patients, training cohort) in the high-risk group achieved PR, it may suggest that when patients with SD are classified into the high-risk group at first evaluation, they may need a more aggressive treatment approach rather than continuing the current treatment to improve the outcomes. Moreover, considering the difference in ORR in the low-risk and high-risk groups, it is worth exploring the application of radiomics analysis in the neoadjuvant chemotherapy of PAC in the future.

Our study has some limitations. First, it was a retrospective study. Prospective studies with more patients are necessary to verify and to improve this RS. Second, CT radiomics analysis was manually performed on a single section of the largest cross-section of the tumor although the potential heterogeneity within tumors might influence the results. In the future, automatic delineation of the whole tumor region of interest, supplemented by manual correction, should be used, which would efficiently promote the translation of radiomics biomarkers into daily practice and clinical trials. Furthermore, the prognostic value of a RS on the basis of the baseline CT scans was not evaluated. Future studies are warranted to determine the performance of a baseline CT signature versus the post-treatment signature and the delta RS (using delta radiomics analysis on the basis of the baseline and initial post-therapy CT data) in predicting the outcomes of patients after chemotherapy. It is also worth exploring the prognostic significance of the radiomics analysis in PR and PD subgroups in the future.

In conclusion, in this study, we generated a RS in patients with advanced PAC and SD disease after first-line chemotherapy. The RS demonstrated favorable predictive efficacy to allow further risk stratification, which would assist oncologists in individualized treatment decision making.

**REFERENCES**

1. Grossberg AJ, Chu LC, Deig CR, et al: Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 70:375-403, 2020
2. Conroy T, Desespoir F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
3. Golan T, Hammel P, Reni M, et al: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317-327, 2019
4. Temporero, MA: NCCN guidelines updates: Pancreatic cancer. J Natl Compr Canc Netw 17:603-605, 2019

**AFFILIATIONS**

1. Department of Medical Imaging Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
2. Department of Pancreatic-Biliary Surgical Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
3. Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
4. Department of Radiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
5. Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center, Shenzhen, China
6. Department of Medical Imaging Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

**CORRESPONDING AUTHOR**

Lizhi Liu, MD, Department of Medical Imaging Center, Sun Yat-sen University Cancer Center, 651 Dongfeng Rd East, Guangzhou, Guangdong 510060, P.R. China; e-mail: liulizhi@sysucc.org.cn.

**DISCLAIMER**

This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal.

**EQUAL CONTRIBUTION**

Q.Y., Y.M., and H.X. contributed equally to this work.

**DATA SHARING STATEMENT**

The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**AUTHOR CONTRIBUTIONS**

Conception and design: Qiuxia Yang, Yize Mao, Tao Qin, Hailin Wen, Yong Li, Rong Zhang, Lizhi Liu
Provision of study materials or patients: Yong Li
Collection and assembly of data: Qiuxia Yang, Tao Qin, Zhijun Mai, Qian Cai, Hailin Wen, Yong Li, Rong Zhang
Data analysis and interpretation: Qiuxia Yang, Yize Mao, Hui Xie, Tao Qin, Hailin Wen, Yong Li, Rong Zhang
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

No potential conflicts of interest were reported.

**ACKNOWLEDGMENT**

We would like to thank Editage (www.editage.com) for English language editing.
5. Perri, G, Prakash L, Qiao W, et al: Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. JAMA Surg 155:832-839, 2020

6. Cai G, Mao Y, Yang Q, et al: Are left ventricular muscle area and radiation attenuation associated with overall survival in advanced pancreatic cancer patients treated with chemotherapyy? Clin Radiol 75:238.e1-238.e9, 2020

7. Barreto SG, Lovejoy B, Windsor JA, et al: Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. ANZ J Surg 89:481-487, 2019

8. Dhir M, Malhotra GK, Sohal DPS, et al: Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol 15:183, 2017

9. Haas M, Waldschmidt DT, Stahl M, et al: Aftabinit plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method. Eur J Cancer 146:95-106, 2021

10. Philip PA, Lucy J, Portales F, et al: Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): A multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 5:285-294, 2020

11. Fernández A, Salgado M, García A, et al: Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study. BMC Cancer 18:1185, 2018

12. Robert M, Jarlier M, Gourgou S, et al: Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma treated with FOLFIRINOX or gemcitabine in a randomized phase III study (ACCORD11/PRODIGE4). Oncology 93:367-376, 2017

13. Meijer LL, Garajova I, Caparello C, et al: Plasma miR-181a-5p downregulation predicts response and improved survival after FOLFIRINOX in pancreatic ductal adenocarcinoma. Ann Surg 271:1137-1147, 2020

14. Shi X, Li Y, Zhang H, et al: A five-microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data. Sci Rep 8:7638, 2018

15. Strijker M, Soer EC, de Pastena M, et al: Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Int J Cancer 146:1445-1456, 2020

16. Creemers A, Kraus S, Strijker M, et al: Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. Biochim Biophys Acta Rev Cancer 1868:394-403, 2017

17. Zhang Y, Zhu L, Wang X: A network-based approach for identification of subtype-specific master regulators in pancreatic ductal adenocarcinoma. Genes (Basel) 11, 115, 2020

18. Kandimalla R, Tomihara H, Banwait JK, et al: A 15-gene immune, stromal, and proliferation gene signature that significantly associates with poor survival in patients with pancreatic ductal adenocarcinoma. Clin Cancer Res 26:3641-3648, 2020

19. Guo J, Zhang P, Zhou L, et al: Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. EBiomedicine 55:102767, 2020

20. Xie T, Wang X, Li M, et al: Pancreatic ductal adenocarcinoma: A radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection. Eur Radiol 30:2513-2524, 2020

21. Nasel H, Zheng C, Schott D, et al: A Machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. NPJ Precis Oncol 3:25, 2019

22. Borhani AA, Dewan R, Furlan A, et al: Assessment of response to neoadjuvant therapy using CT texture analysis in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. AJR Am J Roentgenol 214:362-369, 2020

23. Sandrasegaran K, Lin, Y, Asare-Sawiri, M, et al: CT texture analysis of pancreatic cancer. Eur Radiol 29:1067-1073, 2019

24. Philip PA, Lacy J, Portales F, et al: Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): A multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 5:285-294, 2020

25. Perri G, Prakash L, Qiao W, et al: Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. JAMA Surg 155:832-839, 2020

26. Cai G, Mao Y, Yang Q, et al: Are left ventricular muscle area and radiation attenuation associated with overall survival in advanced pancreatic cancer patients treated with chemotherapyy? Clin Radiol 75:238.e1-238.e9, 2020

27. Barreto SG, Lovejoy B, Windsor JA, et al: Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. ANZ J Surg 89:481-487, 2019

28. Dhir M, Malhotra GK, Sohal DPS, et al: Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol 15:183, 2017

29. Haas M, Waldschmidt DT, Stahl M, et al: Aftabinit plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method. Eur J Cancer 146:95-106, 2021

30. Philip PA, Lucy J, Portales F, et al: Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): A multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 5:285-294, 2020

31. Fernández A, Salgado M, García A, et al: Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study. BMC Cancer 18:1185, 2018

32. Robert M, Jarlier M, Gourgou S, et al: Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma treated with FOLFIRINOX or gemcitabine in a randomized phase III study (ACCORD11/PRODIGE4). Oncology 93:367-376, 2017

33. Meijer LL, Garajova I, Caparello C, et al: Plasma miR-181a-5p downregulation predicts response and improved survival after FOLFIRINOX in pancreatic ductal adenocarcinoma. Ann Surg 271:1137-1147, 2020

34. Shi X, Li Y, Zhang H, et al: A five-microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data. Sci Rep 8:7638, 2018

35. Strijker M, Soer EC, de Pastena M, et al: Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Int J Cancer 146:1445-1456, 2020

36. Creemers A, Kraus S, Strijker M, et al: Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. Biochim Biophys Acta Rev Cancer 1868:394-403, 2017
FIG A1. CONSORT diagram of patients’ recruitment in the (A) primary cohort, (B) internal testing cohort, and (C) external testing cohort. APC, advanced pancreatic adenocarcinoma; CT, computed tomography; MRI, magnetic resonance imaging; PD, progressive disease; PR, partial response; SD, stable disease.
FIG A2. Selection of radiomic features using the least absolute shrinkage and selection operator regression model. (A) LASSO feature selection, (B) Logistic regression model.

FIG A3. The contributing weight bar chart of parameters in the RS. The features with the top-two weights were Inertia_angle45_offset7 (23.7%) and ShortRunHighGreyLevelEmphasis_AllDirection_offset1_SD (19.6%) in the venous phase. The x-axis represents the value of each patient’s contributing weight $F_i$ for each parameter, according to the formula described in the Data Supplement. The percentage in the figure is $F_i$ described in the Data Supplement. SD, stable disease.
FIG A4. The DCA for the radiomics model and clinical features in the four cohorts: (A) training, (B) validation, (C) internal testing, and (D) external testing cohorts. CA 19-9, cancer antigen 19-9; DCA, decision curve analysis.
FIG A5. Serial tumor response after chemotherapy according to risk stratification in the validation cohort. For a tumor response beyond 9 months, only the final outcomes are recorded in the diagram. CT, computed tomography; PD, progressive disease; PR, partial response; pts, patients; SD, stable disease.